AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04336891 — intervention group
Intervention type: DRUG
Intervention: Testosterone gel + Estradiol ovules
Description: Transdermal 2% T gel applied once daily to the thighs or lower abdominal/pubic area (300 mcg T per day), plus Intravaginal estradiol ovules taken daily for 2 weeks and afterwards twice a week, for 6 months
Study NCT04325490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid powder
Description: apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
Study NCT01876069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge ProCore needle aspiration
Description: Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
Study NCT01876069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge Fine needle aspiration
Description: Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
Study NCT00457938 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: low-fat diet ( Still recruiting )
Description: This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
Study NCT00457938 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: 10 % versus 35 % fat in diet
Study NCT03517709 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Primary Care Physician Management of blood pressure
Description: * You will receive a 30-minute education session about your blood pressure medications and the need to take them every day.~* Your primary care physician will make recommendations on your optimal target blood pressure range and medication recommendations. .
Study NCT03517709 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Withings Smart Blood Pressure Monitor
Description: We will use the Withings Smart Blood Pressure Monitor for daily blood pressure measurements.
Study NCT03946397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulstisensory massage
Description: 7 minutes of hand massage followed by multisensory immersion (lights and music) for 23 minutes
Study NCT01462357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: 2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6.
Study NCT01462357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: 2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gardasil 2 dose Group) or at Day 0, Month 2 and Month 6 (Gardasil 3 dose Group), respectively.
Study NCT04325490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone cream 1%
Description: apply the study drug 1 fingertip unit to cover intertrigo lesion twice a day for two weeks.
Study NCT02649673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Study NCT02649673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.
Study NCT02649673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated GCSF (PEG-GCSF)
Description: Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
Study NCT04143815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01 (Botulinum toxin A)
Description: Intramuscular injection, dose varies by groups
Study NCT03265340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dTMS
Study NCT04143815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT01363232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 + MEK162
Study NCT04019028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low frequency rTMS + Navigation System
Description: 1Hz low-frequency rTMS stimulation over primary motor area using navigation system
Study NCT04019028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: only low frequency rTMS
Description: 1Hz low-frequency rTMS stimulation over primary motor area
Study NCT04019028 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham low frequency rTMS + Navigation System
Description: 1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
Study NCT03937882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGN-259
Description: A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
Study NCT03937882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
Study NCT03373916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentorship
Description: The peer mentor will meet with the participant for the first time while the participant is still in the hospital. Sessions will be scheduled according to the participant's preferences, with a suggested maximum frequency of twice weekly for the first two weeks, weekly for weeks 3 to 8, and then every other week for the last month. Allowable meeting locations include public places in the community (e.g., coffee shop, park), the participant's home, or a research clinic space or by phone. Session content is flexible and allows for the peer mentor to provide general supportive listening, validation, and sharing. Session duration is on average 1 hour with at least 15 minutes discussing hope or belongingness according to semi-structured conversation guides. The session structure and content are intentionally highly flexible to allow for genuineness in the peer relationship, thereby increasing acceptability and implicit belongingness.
Study NCT03331757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT03373916 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts.
Study NCT02569398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atabecestat, 5 mg
Description: One atabecestat, 5 mg tablet orally once daily up to 54 months.
Study NCT03331757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fir honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of fir honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT02569398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atabecestat, 25 mg
Description: One atabecestat, 25 mg tablet orally once daily up to 54 months.
Study NCT02569398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One matching placebo tablet orally once daily up to 54 months.
Study NCT03331757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heather honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of heather honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT03331757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrus honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT00451776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Description: patients who received etomidate
Study NCT00451776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: patients who received propofol
Study NCT02326909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
Study NCT02326909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
Study NCT01840332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-thyroxin
Description: Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is \< 30 after 4 weeks the study continues up to 6 weeks.
Study NCT00987909 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Specific allergen immunotherapy (placebo)
Description: Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
Study NCT00987909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Specific allergen immunotherapy
Description: Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
Study NCT00987909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Specific allergen immunotherapy
Description: Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
Study NCT00987909 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Specific allergen immunotherapy
Description: Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
Study NCT04524663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Camostat Mesilate administered as oral tablets
Study NCT01462357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
Study NCT04524663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match camostat mesilate
Study NCT04524663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Treatment
Description: Standard of Care Treatment for COVID-19 Infection
Study NCT01195610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Instruction to diet for 6 month
Study NCT04524663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Treatment
Description: Standard of Care Treatment for COVID-19 Infection
Study NCT00987558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Study NCT00987558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study NCT03461224 — intervention group
Intervention type: RADIATION
Intervention: accelerated hypofractionated RT
Study NCT03461224 — intervention group
Intervention type: RADIATION
Intervention: conventional fractionated RT
Study NCT01106456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: All Nations Breath of Life (ANBL)
Description: ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
Study NCT01106456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nontailored program (NT)
Description: The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current best practice recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
Study NCT01479231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexlansoprazole
Description: Dexlansoprazole 60 mg daily for 6 weeks
Study NCT01461018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune globulin subcutaneous (Human)
Description: IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
Study NCT01698749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long acting intravitreal dexamethasone implant
Description: Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
Study NCT02025127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Enteral nutrition introduced via a feeding tube
Study NCT00467974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEA with LEM
Description: Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)
Study NCT00467974 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transarterial chemoembolisation (TACE)
Study NCT04138758 — intervention group
Intervention type: DRUG
Intervention: Tiotropium bromide + Olodaterol
Description: Tiotropium bromide + Olodaterol
Study NCT04138758 — intervention group
Intervention type: DRUG
Intervention: LABA/ICS
Description: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
Study NCT03999203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid
Description: Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
Study NCT03331757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pine honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of pine honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study NCT03823690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided gastrojejunstomy
Description: As listed in the arms description
Study NCT03823690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The pyloro-duodenal stent
Description: As listed in the arms description
Study NCT03999203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leicester Cough monitor
Description: Ambulatory cough monitor to assess cough frequency over a 24 hour period
Study NCT01106456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
Study NCT03999203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fractional exhaled nitric oxide testing (FeNO)
Description: Measurement of exhaled nitric oxide to give an indication of airway inflammation
Study NCT03999203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcome measures
Description: A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
Study NCT01224249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish and shellfish
Description: Intake of 1000 grams of fish and shellfish per week for six months.
Study NCT03813316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor
Description: Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
Study NCT02464215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.
Study NCT02464215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
Study NCT00558441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVMRI
Description: Intra Vascular Magnetic Resonance Imaging
Study NCT00268697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
Study NCT00268697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and ezetimibe
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
Study NCT00268697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
Study NCT03813316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)
Study NCT03813316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor and DPP-4 inhibitor
Description: Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
Study NCT04251325 — intervention group
Intervention type: OTHER
Intervention: Basic Life Support Courses
Description: 4 hours basic life support courses for laypersons
Study NCT03067870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: * Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.~* Transplantation of autologous bone marrow derived stem cells in joints.
Study NCT02349815 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel (Jaydess, Skyla, BAY86-5028)
Description: Women use Levonorgestrel (Jaydess, BAY86-5028) .
Study NCT04150900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
Study NCT04150900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study NCT00599625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 80mg administered daily for 6 consecutive weeks
Study NCT06092736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Danshen Dropping Pills
Description: Dosage of Compound Danshen Dropping Pills: 20 capsules each time, 3 times a day, after meals. The follow-up period was 6 months.
Study NCT06092736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
Study NCT03665675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
Description: Given intravenously
Study NCT03665675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Description: Given intravenously